Concepedia

H. Lenz

HL

Statistics

Publications

5

Citations

113

H-Index

5

Active since

2004

Affiliations

UPMC Hillman Cancer Center(Current)

H. Lenz is an author at UPMC Hillman Cancer Center specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

2004–2015

5

Publications

5

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

Edward M. Newman, Robert J. Morgan, Shivaani Kummar et al. · Cancer Chemotherapy and Pharmacology · 2015 · 55 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

279 Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin

Eric Van Cutsem, R. John Mayer, Philip J. Gold et al. · European Journal of Cancer Supplements · 2004 · 26 citations

Medicine, Oncology, Pharmacology +16

A phase I study of ABT-888 (A) in combination with metronomic cyclophosphamide (C) in adults with refractory solid tumors and lymphomas.

Shivaani Kummar, A. P. Chen, J. Ji et al. · Journal of Clinical Oncology · 2010 · 12 citations

Medicine, Oncology, Pharmacology +17

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

Josep Tabernero, Robin M.J.M. van Geel, J.C. Bendell et al. · European Journal of Cancer · 2014 · 10 citations

Medicine, Oncology, Pharmacology +12

Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).

M. B. Sawyer, S. Iqbal, H. Lenz et al. · Journal of Clinical Oncology · 2010 · 10 citations

Medicine, Oncology, Pharmacology +16

1–5 of 5